Axim Biotechnologies Reports Third Quarter 2017 Results

­­

NEW YORK, Nov. 22, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced results for the quarter ended September 30, 2017, and provided an overview of recent operational highlights.

“We are very excited to see clinical evidence of our theory and the therapeutic effects of CBD gum and mastication on IBS patients. We learned a great deal from the pilot study that will help us to construct the next steps in our IBS program. We plan to extend this study as an open-label trial for prolonged duration and with set dosing and intervals. This will allow us to analyze the effects of controlled dosing on symptom management,” said Dr. George Anastassov, MD, DDS, MBA and CEO of AXIM Biotechnologies.

“During the quarter, we received two (2) new patent allowances for cannabinoids-based ophthalmic solutions for the treatment

... read more at: https://globenewswire.com/news-release/2017/11/22/1205162/0/en/Axim-Biotechnologies-Reports-Third-Quarter-2017-Results.html

by